During development, cells grow, expand, and migrate to generate tissues and organs in a highly controlled manner. Many ...

Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...

Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share ...

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at ...